| Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation BR Anderson, H Muramatsu, SR Nallagatla, PC Bevilacqua, LH Sansing, ... Nucleic acids research 38 (17), 5884-5892, 2010 | 621 | 2010 |
| Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L BR Anderson, H Muramatsu, BK Jha, RH Silverman, D Weissman, ... Nucleic acids research 39 (21), 9329-9338, 2011 | 368 | 2011 |
| Analysis of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences JA Suhl, P Chopra, BR Anderson, GJ Bassell, ST Warren Human molecular genetics 23 (20), 5479-5491, 2014 | 91 | 2014 |
| Identification of consensus binding sites clarifies FMRP binding determinants BR Anderson, P Chopra, JA Suhl, ST Warren, GJ Bassell Nucleic acids research 44 (14), 6649-6659, 2016 | 65 | 2016 |
| Inhibition of the schizophrenia-associated microRNA miR-137 disrupts Nrg1α neurodevelopmental signal transduction KT Thomas, BR Anderson, N Shah, SE Zimmer, D Hawkins, AN Valdez, ... Cell reports 20 (1), 1-12, 2017 | 58 | 2017 |
| Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK BR Anderson, K Karikó, D Weissman Gene therapy 20 (2), 136-142, 2013 | 41 | 2013 |
| Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis H Liu, RS Kang, K Bagnowski, JM Yu, S Radecki, WL Daniel, ... Journal of Investigative Dermatology 140 (2), 435-444. e4, 2020 | 39 | 2020 |
| A 3′ untranslated region variant in FMR1 eliminates neuronal activity-dependent translation of FMRP by disrupting binding of the RNA-binding protein HuR JA Suhl, RS Muddashetty, BR Anderson, MF Ifrim, J Visootsak, GJ Bassell, ... Proceedings of the National Academy of Sciences 112 (47), E6553-E6561, 2015 | 37 | 2015 |
| FMRP-G-quadruplex mRNA-miR-125a interactions: Implications for miR-125a mediated translation regulation of PSD-95 mRNA B DeMarco, S Stefanovic, A Williams, KR Moss, BR Anderson, GJ Bassell, ... PLoS One 14 (5), e0217275, 2019 | 33 | 2019 |
| Quality control and normalization methods for protein microarrays B Anderson, D Hall, M Groll, C Bingham, J Thompson, R Spendlove US Patent App. 10/943,666, 2006 | 11 | 2006 |
| Topical administration of therapeutic agents and oligonucleotide formulations P Patel, B Anderson US Patent App. 16/095,134, 2019 | 10 | 2019 |
| Spherical nucleic acid tlr9 agonists B Anderson, S Nallagatla, R Kang, E Kandimalla US Patent App. 16/099,404, 2019 | 9 | 2019 |
| Induction of HIV‐specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine JB Wingard, B Anderson, D Weissman European journal of immunology 38 (5), 1310-1320, 2008 | 8 | 2008 |
| Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors R Kang, S Nallagatla, B Anderson, E Kandimalla, M Mutolo US Patent App. 16/976,168, 2021 | 7 | 2021 |
| Abstract A136: AST-008, a novel TLR9 agonist SNA, induces abscopal antitumor effects in mouse tumor models ER Kandimalla, SR Nallagatla, BR Anderson, R Kang Cancer Immunology Research 7 (2_Supplement), A136-A136, 2019 | 6 | 2019 |
| Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) R Kang, S Anantatmula, R Agarwal, M Burkhart, B Anderson US Patent App. 16/074,504, 2020 | 5 | 2020 |
| Tlr9-targeted spherical nucleic acids having potent antitumor activity S Nallagatla, B Anderson, E Kandimalla US Patent App. 16/099,409, 2020 | 5 | 2020 |
| Il-1 beta targeting spherical nucleic acids B Anderson US Patent App. 17/253,102, 2021 | 3 | 2021 |
| Spherical nucleic acids targeting toll-like receptor 9 enhance antitumor activity in combination with anti-PD-1 antibody in mouse tumor models SR Nallagatla, BR Anderson, S Anantatmula, ER Kandimalla Cancer Research 77 (13_Supplement), 4706-4706, 2017 | 3 | 2017 |
| Spherical nucleic acid tlr9 agonists B Anderson, S Nallagatla, R Kang, E Kandimalla US Patent App. 17/231,896, 2022 | 2 | 2022 |
